Markedly, transcriptional heterogeneity has been associated with therapy resistance in breast cancer [71]; and in EGFR mutant NSCLC, MET overexpression is associated with resistance to tyrosine kinase inhibitors(TKI) [91,92]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.